Avadel Pharmaceuticals plc (AVDL)

Avadel Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	79.81	51.37	31.17	73.98	50.71	71.72
Short-Term Investments	11.76	22.41	73.94	22.52	106.51	151.16
Cash & Short-Term Investments	91.58	73.78	105.11	96.5	157.22	222.88
Cash Growth	39.16%	-29.81%	8.92%	-38.62%	-29.46%	247.39%
Accounts Receivable	42.44	34.1	12.1	-	-	-
Other Receivables	-	-	-	2.25	31.54	38.44
Receivables	42.44	34.1	12.1	2.25	31.54	38.44
Inventory	23.91	20.3	10.38	-	-	-
Prepaid Expenses	13.5	5.15	4.37	1.52	3.18	1.02
Other Current Assets	0.8	0.88	2.24	0.57	0.55	1.12
Total Current Assets	172.23	134.21	134.2	100.84	192.49	263.45
Property, Plant & Equipment	10.16	12.86	13.08	13.24	11.49	8.16
Goodwill	16.84	16.84	16.84	16.84	16.84	16.84
Long-Term Deferred Tax Assets	-	-	-	-	24.13	18.26
Other Long-Term Assets	0.22	0.34	0.58	1.87	2.33	4.93
Total Assets	199.45	164.24	164.7	132.79	247.27	311.64

Liabilities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Accounts Payable	12.58	7.33	11.43	7.89	7.68	2.93
Accrued Expenses	27.72	24.54	19.45	8.51	12.03	8.68
Current Portion of Long-Term Debt	-	1.89	0.73	37.67	-	-
Current Portion of Leases	0.74	0.58	0.93	0.96	0.9	0.47
Other Current Liabilities	21.45	14.49	4.31	0.77	0.39	3.03
Total Current Liabilities	62.49	48.83	36.86	55.79	21	15.11
Long-Term Debt	34.83	35.25	32.76	91.61	142.4	128.21
Long-Term Leases	1.81	1.12	1.69	0.78	1.71	1.84
Other Long-Term Liabilities	2.1	5.18	5.65	5.74	3.92	4.21
Total Liabilities	101.22	90.39	76.96	153.93	169.02	149.37

Shareholders' Equity

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Common Stock	0.97	0.97	0.9	0.63	0.59	0.58
Additional Paid-In Capital	910.39	891.79	855.45	589.78	549.35	566.92
Retained Earnings	-789.56	-794.33	-745.5	-585.22	-447.76	-384.19
Comprehensive Income & Other	-23.58	-24.58	-23.17	-26.34	-23.94	-21.05
Total Common Equity	98.23	73.85	87.69	-21.15	78.24	162.26
Shareholders' Equity	98.23	73.85	87.74	-21.15	78.24	162.27
Total Liabilities & Equity	199.45	164.24	164.7	132.79	247.27	311.64

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Debt	37.38	38.84	36.11	131.02	145	130.52
Net Cash (Debt)	54.2	34.93	69	-34.52	12.22	92.36
Net Cash Growth	96.71%	-49.37%	-	-	-86.77%	-
Net Cash Per Share	0.56	0.37	0.86	-0.57	0.21	1.68
Filing Date Shares Outstanding	97.66	96.63	90.58	64.48	59.03	58.47
Total Common Shares Outstanding	97.24	96.52	89.83	62.88	58.62	58.4
Working Capital	109.74	85.37	97.35	45.05	171.49	248.35
Book Value Per Share	1.01	0.77	0.98	-0.34	1.33	2.78
Tangible Book Value	81.39	57.01	70.85	-37.99	61.4	145.43
Tangible Book Value Per Share	0.84	0.59	0.79	-0.60	1.05	2.49
Machinery	-	0.63	0.63	0.63	0.3	0.3

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error